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Purpose. To identify an animal model for the abnormal scotopic electroretinogram found in
a majority of Duchenne and Becker muscular dystrophy patients.
Methods. Ganzfeld electroretinograms were recorded in dark-adapted normal C57BL/6 mice,
and two strains of mice with different X-linked muscular dystrophy mutations {mdx and
mdxCv}). Responses for the right eye were averaged and the amplitudes and implicit times of
the a-wave and b-wave were measured. The electroretinogram was digitally filtered to extract
the oscillatory potentials. Statistical analyses included one-way analysis of variance and the
Scheffe S test.
Results. While the electroretinogram in mdx was normal, in mdxCv3 the scotopic b-wave was
markedly reduced and the oscillatory potentials were delayed, similar to changes observed in
Duchenne and Becker muscular dystrophy patients. Some of the mdx<J"3 animals demonstrated
negative configuration electroretinograms, with the b-wave amplitude reduced compared to
that of the a-wave.
Conclusions. Abnormalities found in the electroretinograms of Duchenne and Becker muscular
dystrophy patients led to the identification of dystrophin in human retina and the discovery
that dystrophin is required for normal retinal electrophysiology. These results indicate that
mdxc"3 is a model for elucidating the role of dystrophin in retina and suggest that dystrophin
isoforms, consisting of only the C-terminal domains of the full-length protein, may be im-
portant to the development of normal retinal electrical potentials. Invest Ophthalmol Vis Sci.
1995; 36:462-466.
.fcjlectroretinographic (ERG) examination of a group
of patients with a contiguous deletion syndrome at
Xp21, which includes Duchenne or Becker muscular
dystrophy (DMD/BMD), glycerol kinase deficiency,
and congenital adrenal hypoplasia, revealed a com-
mon, abnormal phenotype characterized by a reduced
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scotopic b-wave.1 s Most patients with only DMD or
BMD manifest this characteristic ERG abnormality,
even though other aspects of their eye examinations
do not differ from normal.4"7 This suggests that dys-
trophin, the protein defective in DMD/BMD pa-
tients,8 is important to the development of normal
retinal electrical potentials. Specific antibodies have
been used to demonstrate that dystrophin in retina is
localized in the outer plexiform layer,9"11 which is the
site of synaptic contact between photoreceptors and
bipolar cells, and which has been linked to the ERG
b-wave.12"14
Dystrophin is expressed in multiple isoforms re-
sulting from differential promoter usage and alterna-
tive splicing. The full-length isoform is a 427-kd mem-
brane-associated protein that is encoded by a 14-kb
mRNA.8'15'16 At least three different muscle and brain
promoters are located in the 5' end of the gene, each
of which direct transcription through different 5' first
exons.17'18 In a number of other tissues, shorter iso-
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forms of the protein are expressed from additional
promoters located within the 3' end of the gene.19"21
One promoter, situated between exons 62 and 63
leads to the expression of a ~5 kb mRNA and a 71
kd isoform of dystrophin referred to as apodystrophin,
DP71, or nonmuscle dystrophin. Multiple isoforms of
dystrophin are expressed in retina from both muscle
and nonmuscle promoters.9 The function of these iso-
forms in retina and other tissues is unknown.
Studies of patients with DMD deletions have
shown that the location of the deleted sequence can
affect the ERG phenotype.7 Mutations in the central
region or in the 3' end of the gene are associated
with severe reductions in b-wave amplitude, whereas
deletions limited to the 5' end of the gene appear to
be associated with milder abnormalities and in some
cases normal ERGs.7 To explore this further, we de-
cided to screen dystrophic (mdx) mouse strains with
different mutations in the dystrophin gene to deter-




We studied the scotppic electroretinogram in four
mdx, five mdxCv3, and seven control C57BL/6 mice.
The mdx mouse has a point mutation in exon 23 at
the 5' end of the dystrophin gene, whereas the mdxCv3
mouse has a point mutation in intron 65, near the 3'
end.22"25 Only male mice were tested. The average age
and weight of the mice at time of testing did not differ
significantly among the three groups (range, 20-24
weeks, approximately 30 g). The breeding, housing,
and use of animals was within institutional guidelines
for the Oregon Health Sciences University and con-
formed with the ARVO Statement for the Use of Ani-
mals in Ophthalmic and Vision Research.
Electroretinography
Ganzfeld ERGs were recorded after 6 hours of dark
adaptation. Animals were anesthetized by subcutane-
ous injection of 0.09 ml of a mixture of ketamine (27.8
mg/ml), xylazine (2.8 mg/ml), and acepromazine
(0.56 mg/ml). The right eye pupil was dilated with a
drop of 1% atropine and the cornea was anesthetized
with a drop of 0.5% proparacaine-HCl ophthalmic so-
lution. Responses were recorded from the cornea us-
ing a saline-soaked, cotton-wick electrode; ground and
reference needle electrodes were inserted subcutane-
ously in the dorsal neck region. A stimulator (Grass
[Quincey, MA] PS22) mounted in a Ganzfeld dome
produced an integrated white-light value of 7.6 cd-s/
m2 at the plane of the eye. Ten responses separated in
their presentation by 20 seconds were averaged using a
mdx mdxCv3
FIGURE 1. Representative full-frequency Ganzfeld electroreti-
nograms (A), and digitally isolated oscillatory potentials (B),
for C57BL/6, mdx, and mdxCv3 mice showing normal wave-
forms for the mdx mouse and severely reduced amplitude
and delayed b-wave and prolonged oscillatory potentials for
the mdxCv3 mouse. The peaks of the a-waves and b-waves are
indicated and individual oscillatory potentials are numbered
for the C57BL/6 mouse. Implicit times (in milliseconds)
are measured from the stimulus marker to the peak for
the a-waves, b-waves and oscillatory potentials. In row B the
horizontal arrows denote the implicit time of the largest
wavelet, OP3.
band-pass frequency of 0.1 to 1000 Hz. The amplitude
and implicit time (time to peak) of the a-wave (a nega-
tive potential reflecting the photoreceptor hyperpo-
larization light response) and the b-wave (a positive
potential reflecting contributions of bipolar and/or
Miiller cells) were measured. The full spectrum ERG
(0.1 to 1000 Hz) was digitally filtered to extract com-
ponent frequencies of 100 to 300 Hz, the so-called
oscillatory potentials.26 The oscillatory potentials are
wavelets superimposed on the ascending portion of
the b-wave and are thought to represent repetitive
inhibitory firing of amacrine cells.27
Statistical Analyses
One-way analysis of variance was performed on ages
and all ERG results using SuperANOVA (Version
1.1.1, Abacus Concepts, Inc., Berkeley, CA). When the
between-groups F-test indicated differences at a proba-
bility of P < 0.01, differences were sought among the
groups using post hoc comparison tests. We accepted
as significant changes that achieved a 0.01 significance
level with the Scheffe S test.
RESULTS
The ERGs from the mdx mouse were indistinguishable
from those of the control strain (Fig. 1A, left and
middle panels), consistent with the recently reported
results of Cibis and colleagues.28 Conversely, although
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TABLE l. Electroretinogram Responses for Control, mdx, and mdxCv3 Mice
Group
C57BL/6 (n = 7)
Mean
SD
mdx (n = 4)
Mean
SD







































































































* Only the largest waveform, OP-3, is presented. Analysis of all other peaks reached similar significance levels.
f 0.01 significance level by the Scheffe S test.
X Although not significant at the 0.01 significance level, this comparison was significant at the 0.05 level {P = .0334) by the Scheffe S
test.
NS = ANOVA not significant at 0.01 level; no post hoc comparisons performed; ANOVA = analysis of variance.
the mdxCvS has a normal a-wave amplitude and latency
to peak (implicit time), its b-wave was attenuated by
more than 50% and had a prolonged implicit time
when compared to control and mdx mice29 (Fig. 1A,
right panel; Table 1). The ratio of b-wave to a-wave
amplitude was significantly lower in mdxCv3 mice than
in control or mdx mice (Table 1). The amplitudes of
the oscillatory potentials did not differ significantly
among the three groups (Table 1). The implicit times
of the oscillatory potentials, while normal for the mdx
strain, were delayed by nearly 50% for the mdxCv3 strain
(Fig. IB and Table 1).
DISCUSSION
The original mdx mouse was identified by phenotypic
screening of a mouse colony for spontaneous mu-
tants.22 The mdx mouse mutation was identified
as a point mutation in exon 23 near the 5' end of
the DMD gene leading to a truncated, unstable pro-
tein.23"24 However, in this mouse the expression of
the 71 kd nonmuscle dystrophin isoform is normal
because the mdx mutation is upstream of the nonmus-
cle promoter!25 Immunohistochemistry using antibod-
ies directed at the carboxy terminus of dystrophin con-
firm that this domain is expressed in mdx retina.1011
Chapman and colleagues recently isolated addi-
tional dystrophic mouse strains by injecting normal
C57BL/6 mice with the chemical mutagen N-ethylni-
trosourea and screening progeny for elevated levels
of creatine phosphokinase.30 This method generated
four new dystrophic strains with mutations in the dmd
gene. Affected male mice demonstrated elevated cre-
atine phosphokinase, pseudomyotonia on electromyo-
gram, and skeletal muscle fiber degeneration, consis-
tent with human DMD and BMD. The clinical pheno-
type of the mice is mild, however, similar to that of
BMD.
The molecular basis of the mutation in one of
these strains, mdxCv3, involves a T to A transversion
that creates a novel AG splice acceptor site 14 bp up-
stream of the normal site within intron 65 at the 3'
end of the gene.25'30 The 71 kd isoform of dystrophin
present in mdx mice is thus absent in mdxc"3.25
The ERG abnormalities identified for the male
mdxCv3 mice are similar to those seen in males with
DMD/BMD25 and indicate that the mdxCv3 mouse is a
valuable model for studying the electrophysiological
changes seen in the retina.
The position of the mutation within the dys-
trophin gene appears to influence the severity of the
ERG phenotype in DMD/BMD patients, as evidenced
by the mild abnormalities found in some patients with
deletions within the 5' portion of the gene and normal
ERGs in many nondeletion patients.7 The same posi-
tion effects appear to be operative in the mouse, inas-
much as the mdx mutation lies within the 5' end of
the dystrophin gene, and the ERG in this mutant is
normal. In contrast, in the mdxCv3 whose mutation is
located in the 3' end of the gene, the amplitude of
the b-wave is attenuated and the implicit times of the
b-wave and oscillatory potentials are delayed, similar
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to ERG findings in patients with mutations in the 3'
end of the DMD gene.1'37
The correlation between variation in ERG pheno-
type and the location of DMD gene defects indicates
that differential expression of dystrophin isoforms can
influence the electrophysiological function of the ret-
ina. Furthermore, the expression of the 71 kd isoform
of dystrophin in mdx, and its lack of expression in
mdxCv3,25 suggests that defects in this isoform may play
a role in the electrophysiological anomalies observed
in mdxCv3.
The nature of the ERG abnormalities may provide
clues to the function of dystrophin in retina. The re-
duction in amplitude and delay of the b-wave may
reflect alterations in the kinetics of electrophysiologi-
cal events in the outer plexiform layer, the site of
origin of the b-wave. This is consistent with the immu-
nocytochemical localization of dystrophin to the outer
plexiform layer of the retina.9 The oscillatory poten-
tials are thought to originate in the inner plexiform
layer.23 Although any process that delays the b-wave
could be expected to delay the oscillatory potentials,
it is also possible that an independent mechanism,
such as activity in the OFF-pathways, could be in-
volved. Thus, it may be significant that both the b-
wave and the oscillatory potentials are delayed in the
mdxCv3 mouse.
The full-length isoform of dystrophin is thought
to function as part of the cytoskeleton in muscle and
is associated with the sarcolemma.16 Moreover, dys-
trophin isoforms may be involved in calcium transport
in muscle.31 Although the function of the 71 kd iso-
form is unknown, a defect in handling calcium in bi-
polar cells could account for the abnormalities seen
in the ERGs of mdxCv3 mice and DMD/BMD patients.
Dystrophin has been localized to a postsynaptic posi-
tion in other tissues. If a similar location is involved
in retina, dystrophin defects could interfere with b-
wave generation through an effect on synaptic trans-
mission between photoreceptors and rod bipolar cells,
on the properties of the bipolar cell membrane, or
on Muller cell ionic conductances.
The finding of electroretinographic abnormalities
in patients with isolated DMD or BMD has not been
associated with any clinically significant functional
deficits.7'9 Visual acuities, visual fields, and 45-minute,
dark-adapted rod psychophysical thresholds were nor-
mal in BMD patients (R.G. Weleber, unpublished
data) .7>9 This suggests that disorders with abnormal b-
waves and clinical deficits, such as congenital station-
ary night blindness and some forms of retinitis pig-
mentosa,32 may differ in the site of the defect in the
pathway that generates normal retinal electrical po-
tentials.
The mdxc"3 muscular dystrophy mouse is an im-
portant model for studying the molecular mechanisms
underlying the retinal electrophysiological abnormali-
ties in DMD/BMD patients. The alterations in the
mdxCv3 ERGs include reduced amplitude and delayed
b-wave potentials, and delayed oscillatory potentials.
Clarification of these findings will lead to a better
understanding of the role of specific dystrophin iso-
forms in muscle and other tissues. Moreover, such
studies may provide new insight into the molecular
mechanisms underlying abnormalities of the ERG b-
wave in other retinal disorders.
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